Table 2.
Univariate and Multivariate Analyses of Clinicopathological and POH1 Expression for Overall Survival in CRC Patients (n=315)
| Variables | Univariate Analysis |
Multivariate Analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Age (<59 vs. ≥59 years) | 1.047 (0.732-1.497) | .803 | ||
| Gender (female vs. male) | 0.954 (0.661-1.376) | .800 | ||
| BMI (<24 vs. ≥24) | 1.546 (1.072-2.231) | .020 | 1.593 (1.092-2.325) | .016 |
| Hypertension (yes vs. no) | 1.373 (0.923-2.042) | .118 | ||
| Diabetes (yes vs. no) | 2.084 (1.311-3.312) | .002 | 2.025 (1.253-3.274) | .004 |
| T stage(I-II vs. III-IV) | 2.995 (1.647-5.445) | .000 | 1.941 (0.898-4.195) | .092 |
| Metastasis (yes vs. no) | 4.015 (2.725-5.917) | .000 | 0.477 (0.241-0.945) | .034 |
| TNM (I-II vs. III-IV) | 5.212 (3.438 -7.900) | .000 | 5.931 (2.692-13.07) | .000 |
| LNM (yes vs. no) | 2.182 (1.497-3.181) | .000 | 2.182 (1.361-3.497) | .001 |
| Tumor differentiation | 1.496 (0.963-2.325) | .073 | ||
| R0 resection (yes vs. no) | 0.466 (0.301-0.719) | .001 | 0.509 (0.321-0.807) | .004 |
| CEA (<5 vs. ≥5 μg/l) | 2.345 (1.590-3.458) | .000 | 1.277 (0.828-1.968) | .268 |
| CA19-9 (<37 vs. ≥37 U/ml) | 3.149 (2.182-4.545) | .000 | 1.251 (1.761-3.981) | .000 |
| POH1 expression (low vs. high) | 1.983 (1.135-3.465) | .016 | 1.848 (1.031-3.310) | .039 |
BMI, body mass index; LNM, lymph node metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; HR, hazard ratio; CI, confidence interval.